Experience

Novome Biotechnologies

• United States
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder

  • Mar 2016 - Present

  South San Francisco, CA Developing engineered therapeutic bacteria for precise mechanistic treatment of chronic diseases. At Novome, I have worked on expanding core platform technology for reliable and reversible colonization of therapeutic bacterial strains, establishing bespoke animal models for target disease indications, and managing pre-clinical R&D efforts for our first drug program in hyperoxaluria. I am currently focused on managing growth of our team through hiring and recruiting efforts, building a… Show more Developing engineered therapeutic bacteria for precise mechanistic treatment of chronic diseases. At Novome, I have worked on expanding core platform technology for reliable and reversible colonization of therapeutic bacterial strains, establishing bespoke animal models for target disease indications, and managing pre-clinical R&D efforts for our first drug program in hyperoxaluria. I am currently focused on managing growth of our team through hiring and recruiting efforts, building a robust intellectual property portfolio, and directing our organizational development. Show less



Stanford University

• United States
• Higher Education
• 700 & Above Employee

• PhD Student

  • Sep 2012 - Aug 2017

  Stanford, CA Studied in Justin Sonnenburg's lab, developing tools to engineer symbiotic gut bacteria of the genus Bacteroides. Discovered a novel secreted protein from Bacteroides thetaiotaomicron and developed a system using this protein to secrete peptide cargo from diverse members of the Bacteroides genus. Developed a system to reliably integrate and control population size of Bacteroides strains of interest across diverse gut microbial communities in a highly tunable manner. Inventor on two patents and… Show more Studied in Justin Sonnenburg's lab, developing tools to engineer symbiotic gut bacteria of the genus Bacteroides. Discovered a novel secreted protein from Bacteroides thetaiotaomicron and developed a system using this protein to secrete peptide cargo from diverse members of the Bacteroides genus. Developed a system to reliably integrate and control population size of Bacteroides strains of interest across diverse gut microbial communities in a highly tunable manner. Inventor on two patents and author on two publications (Cell and Nature) relating to this work. Show less



University of Washington

• United States
• Higher Education
• 700 & Above Employee

• Research Assistant

  • Jan 2011 - Jun 2012

  Seattle, WA Worked in David Baker's lab, using computational and chemical protein design methods for protein engineering. Rationally re-designed the active site of an acid-stable serine protease to target the immunogenic portion of the gluten protein. Improved activity on target protein by over 100-fold. Demonstrated stability of the engineered enzyme in the presence of gastric proteases. The enzyme formed the basis for the startup PVP Biologics, entered Phase I clinical trials, and PVP was eventually… Show more Worked in David Baker's lab, using computational and chemical protein design methods for protein engineering. Rationally re-designed the active site of an acid-stable serine protease to target the immunogenic portion of the gluten protein. Improved activity on target protein by over 100-fold. Demonstrated stability of the engineered enzyme in the presence of gastric proteases. The enzyme formed the basis for the startup PVP Biologics, entered Phase I clinical trials, and PVP was eventually acquired by Takeda. Inventor on one patent and author on one publication (JACS) relating to this work. Show less



Seattle Children's

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Research Assistant

  • Feb 2010 - Jun 2012

  Seattle, WA Worked in Mark Majesky's lab, studying the developmental mechanisms linked to coarctation of the aorta, a congenital heart defect. Examined the molecular mechanisms regulating formation of the ductus arteriosus-aorta boundary, and potential contributions of this cell lineage boundary to coarctation of the aorta. Managed timed mating and custom genotyping for 26 different transgenic mouse lines.